Francisco Casas-Maldonado1, Francisco-Javier Álvarez-Gutiérrez2, Marina Blanco-Aparicio3, Christian Domingo-Ribas4,5, Carolina Cisneros-Serrano6,7, Gregorio Soto-Campos8, Berta Román-Bernal9, Francisco-Javier González-Barcala10,11,12,13. 1. Servicio de Neumología, Hospital Universitario Clínico San Cecilio, Granada, España. 2. Servicio de Neumología, Hospital Universitario Virgen del Rocío, Sevilla, España. 3. Servicio de Neumología, Hospital Universitario A Coruña, A Coruña, España. 4. Servei de Pneumologia, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, España. 5. Departament de Medicina, Universitat Autònoma de Barcelona (UAB), Bellaterra, Barcelona, España. 6. Servicio de Neumología, Hospital Universitario La Princesa, Madrid, España. 7. Fundación de Investigación Biomédica La Princesa, Madrid, España. 8. Servicio de Neumología y Alergia, Hospital Universitario de Jerez, Jerez de la Frontera, Cádiz, España. 9. Neumología, Hospital Dr. José Molina Orosa, Arrecife, Las Palmas, España. 10. Servicio de Neumología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, España. 11. Departamento de Medicina, Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, España. 12. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias - CIBERES, Madrid, España. 13. Grupo Translational Research in Airway Diseases-FIDIS, Santiago de Compostela, A Coruña, España.
Abstract
BACKGROUND: Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments. OBJECTIVE: To evaluate the proportion of patients with SUA treated with mABs in Spain, and to analyze some of the factors that could determine these prescription patterns. METHODS: An analysis was performed on the data provided from the Hospitals National Health System (NHS) 2018 catalogue where Chest Diseases Department and a Hospital Pharmacy were available. Random sampling was performed to determine the sample size, stratifying proportionally by geographic area and hospital level. Characteristics of the participating sites, as well as the prescribing of mABs were collected, which included geographic area, hospital levels, prescribing medical specialities, types of clinics, and mABs prescribed. RESULTS: Data from 90 hospitals were analyzed (Response rate 64.3%). Level 4 hospitals, the Canary Islands geographical area, and the presence of a high complexity Asthma Healthcare Unit (ACU) were associated with a higher probability that the SUA was treated with mABs. CONCLUSION: The map of the prescribing of mABs for SUA in Spain shows a significant variation by geographic area, hospital level, type of clinic, and the accreditation level of the ACUs. At the current time, there appears to be significant under-prescribing of these treatments.
BACKGROUND: Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments. OBJECTIVE: To evaluate the proportion of patients with SUA treated with mABs in Spain, and to analyze some of the factors that could determine these prescription patterns. METHODS: An analysis was performed on the data provided from the Hospitals National Health System (NHS) 2018 catalogue where Chest Diseases Department and a Hospital Pharmacy were available. Random sampling was performed to determine the sample size, stratifying proportionally by geographic area and hospital level. Characteristics of the participating sites, as well as the prescribing of mABs were collected, which included geographic area, hospital levels, prescribing medical specialities, types of clinics, and mABs prescribed. RESULTS: Data from 90 hospitals were analyzed (Response rate 64.3%). Level 4 hospitals, the Canary Islands geographical area, and the presence of a high complexity Asthma Healthcare Unit (ACU) were associated with a higher probability that the SUA was treated with mABs. CONCLUSION: The map of the prescribing of mABs for SUA in Spain shows a significant variation by geographic area, hospital level, type of clinic, and the accreditation level of the ACUs. At the current time, there appears to be significant under-prescribing of these treatments.
Entities:
Keywords:
Benralizumab; Dupilumab: Omalizumab; Mepolizumab; Reslizumab; Severe asthma; monoclonal antibodies
Authors: Luis A Pérez de Llano; Borja G Cosío; Ignacio Lobato Astiárraga; Gregorio Soto Campos; Miguel Ángel Tejedor Alonso; Nuria Marina Malanda; Alicia Padilla Galo; Isabel Urrutia Landa; Francisco J Michel de la Rosa; Ismael García-Moguel Journal: J Asthma Allergy Date: 2022-01-14